Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Atezolizumab + Carboplatin + Etoposide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Atezolizumab||Tecentriq||RG7446|MPDL3280A||Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 93||Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy or progressed on platinum-based chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>=50% or IC>=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound in advanced or metastatic triple-negative breast cancer expressing PD-L1, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, and in combination with cobimetinib and vemurafenib in BRAF V600-mutated melanoma (FDA.gov).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Etoposide||Vepesid||EPEG|Eposin|VP-16|VP-16-213||TOPO2 inhibitor 5||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03811002||Phase II||Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide||Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer||Recruiting||USA||1|
|NCT04610684||Phase II||Atezolizumab Atezolizumab + Carboplatin + Etoposide||Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases||Recruiting||USA||0|
|NCT05091567||Phase III||Atezolizumab + Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide + Lurbinectedin||A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)||Recruiting||USA | ITA | ESP | DEU | BEL||8|
|NCT04923776||Phase II||Atezolizumab + Carboplatin + Etoposide||Liver Directed RT + Chemo-immunotherapy for ES-SCLC||Recruiting||USA||0|
|NCT05058651||Phase II||Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide||Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Metastatic Small Cell Neuroendocrine Carcinomas That Originate Outside the Lung||Recruiting||USA||0|
|NCT05224141||Phase III||Carboplatin + Etoposide + MK-7684A Cisplatin + Etoposide + MK-7684A Atezolizumab + Cisplatin + Etoposide Atezolizumab + Carboplatin + Etoposide||Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)||Recruiting||USA | ITA | FRA | ESP | DEU | AUT||13|
|NCT05312671||Phase II||Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide||Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer||Recruiting||USA||0|
|NCT03041311||Phase II||Atezolizumab + Carboplatin + Etoposide + Trilaciclib Atezolizumab + Carboplatin + Etoposide||Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)||Terminated||USA | FRA | ESP||4|
|NCT02748889||Phase Ib/II||Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide||Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer||Terminated||USA||0|
|NCT02763579||Phase III||Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide||A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133)||Active, not recruiting||USA | ITA | FRA | ESP | DEU | AUT||15|
|NCT04256421||Phase III||Atezolizumab + Carboplatin + Etoposide + Tiragolumab Atezolizumab + Carboplatin + Etoposide||A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02)||Active, not recruiting||USA | ITA | ESP | DEU | BEL | AUT||17|
|NCT04487756||Phase Ib/II||Atezolizumab + Carboplatin + Etoposide||Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer (VENEZO-LUNG)||Recruiting||ESP||0|